N
Neurimmune Holding
A biopharmaceutical company dedicated to the development of innovative immunotherapeutics for human diseases
About Neurimmune Holding
Neurimmune is a biopharmaceutical company focused on translating human immune memory into antibody therapeutics. The company operates in the biopharmaceutical market, primarily targeting neurodegenerative diseases such as Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis (ALS). Neurimmune's business model involves discovering and developing antibody-based therapies and then licensing these discoveries to larger pharmaceutical companies for further development and commercialization. For instance, Neurimmune discovered aducanumab, an antibody for Alzheimer's disease, which was licensed to Biogen for further development and submission to the U.S. Food and Drug Administration (FDA). The company generates revenue through licensing agreements, research collaborations, and milestone payments from its partners. Neurimmune serves a global market, collaborating with both academic institutions and industry partners to advance its pipeline of therapeutic candidates. The company's innovative approach leverages the natural immune response to create treatments that can potentially transform the lives of patients with debilitating diseases.
Source: Dealroom company dataNews
Open roles
Neurimmune Holding in the Zurich ecosystem
The Neurimmune Holding office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later1 investor entered at this stage
Biogen
Source: Dealroom Talent Intelligence.
See Neurimmune Holding on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

